Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline results expected in the first half of 2027Strong balance sheet, bolstered by approximately $269.4 million in net proceeds from recent public offering Ended the quarter with$513.0 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations into ...